Cargando…
Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign
Covid-19 urges a deeper understanding of the underlying molecular mechanisms involved in illness progression to provide a prompt therapeutical response with an adequate use of available drugs, including drug repurposing. Recently, it was suggested that a dysregulated bradykinin signaling can trigger...
Autores principales: | Gomez-Gutierrez, Patricia, Perez, Juan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796052/ https://www.ncbi.nlm.nih.gov/pubmed/33383825 http://dx.doi.org/10.3390/ijms22010257 |
Ejemplares similares
-
Function and structure of bradykinin receptor 2 for drug discovery
por: Shen, Jin-kang, et al.
Publicado: (2022) -
Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors
por: Rasaeifar, Bahareh, et al.
Publicado: (2020) -
Oxetanes in
Drug Discovery Campaigns
por: Rojas, Juan J., et al.
Publicado: (2023) -
D-Arg(0)-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B(2) Receptor Agonist Metabolically Activated by Carboxypeptidases
por: Bachelard, Hélène, et al.
Publicado: (2018) -
In Vivo Effects of Bradykinin B(2) Receptor Agonists with Varying Susceptibility to Peptidases
por: Jean, Mélissa, et al.
Publicado: (2016)